INDEMNIFICATION AGREEMENTIndemnification Agreement • June 26th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [l], by and between INHIBRX, INC., a Delaware corporation (the “Company”), and [l] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
Option and License AgreementOption and License Agreement • June 26th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and License Agreement (this “Agreement”), effective as of June 9, 2020 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
INHIBRX, INC. AMENDMENT TO CONVERTIBLE PROMISSORY NOTEPurchase Agreement • June 26th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDMENT (the “Amendment”) to that certain Convertible Promissory Note listed on Schedule A hereto (the “Note”) issued pursuant to the terms of that certain Note Purchase Agreement by and among the Inhibrx, Inc., a Delaware corporation (the “Company”) and DRAGSA 50 LLC (the “Investor”), dated as of May 20, 2019 (the “Purchase Agreement”), is entered into as of April 6, 2020, by and between the Company and the Investor. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Note.
